Pipeline
NeOnc is actively pursuing the commercialization of its drug delivery technology with initial product candidates designed to address specific disease models where direct delivery to the CNS benefits over traditional delivery methods.
Product Development and Clinical Pipeline
NeOnc is currently pursuing validation and regulatory approval for four product candidates, including its NEO100-01/02 POH formulation, (Miligant glioma grade lll and lV IDH1 mutations and Meningiomas), NEO212, a combinatorial formulation of POH and TMZ for the treatment of glioblastoma multiforme cancers, and its NEO100-03 Pediatric formulation for treating patients with Pediatric High-Grade Gliomas (pHGGS) brain tumors.
